Development Archives - Page 2 of 14

Chart of the Week: 3x Improvement in Likelihood of Approval

Sep 12, 2016 | News

In May we released a report co-authored with BIO and BioMedTracker. One of the key take-aways from the report is that patient selection biomarkers, if used successfully, can triple the Likelihood of Approval (LOA) for clinical studies. Here is the data: Share this...

Chart of the Week: Panels Emerging, Single Biomarker Tests Dominate

Jun 14, 2016 | Biomarkers, News

For the chart of the week we wanted to explore the market for multi-analyte panels. We found that single biomarker tests still vastly outnumber panels. Stay tuned for more trending information in the coming weeks. My hypothesis: Panels, even outside of NGS, are...

Chart of the Week: Personalized Medicine Dependent on Time to Market

Apr 12, 2016 | News

In a CotW a few weeks ago we postulated that based on biomarker discovery work Celgene is poised to dominate personalized medicine. However, this week’s chart suggests that if Celgene’s rise in personalized medicine is to happen it could be a long ways...

Amplion adds 10,165 LDTs to BiomarkerBase from almost all LDT developers: addition could be most comprehensive coverage of LDTs available.

Apr 12, 2016 | News

In mid-2015 we worked hard to add a new source of evidence for biomarkers: Laboratory Developed Tests, or LDTs. This was a huge milestone for Amplion. We successfully used our technology to identify biomarkers in a new information source very quickly without...

Chart of the Week: Innovative Biopharma = Faster Biomarkers to Trial

Apr 6, 2016 | News

A few months ago we investigated the use of unique biomarkers by big biopharma. The use of unique biomarkers served as a measure of innovation for each of the biggest biopharma companies. The most innovative companies are progressing biomarkers to trials more...

« Older Entries

Next Entries »